Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an update.
Faron Pharmaceuticals has announced its financial reporting dates for 2026, with the full-year 2025 financial statement release scheduled for March 4 and the half-year financial report set for August 26. The Annual General Meeting is planned for March 30, 2026. This schedule provides stakeholders with key dates to anticipate updates on the company’s financial health and strategic direction.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. The company’s mission is to expand the reach of immunotherapy by discovering new methods to control and utilize the immune system. Its lead product, bexmarilimab, is an innovative macrophage-guiding immunotherapy being tested in various oncology settings.
See more data about FARN stock on TipRanks’ Stock Analysis page.